← All trials
NCT05128539
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Feb 12, 2024
- Completion date
- Apr 27, 2024
- First posted
- Nov 22, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 114
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai Junshi Bioscience Co.,Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.